CA3177643A1 - System and method of measuring venous oxygen saturation using intelligent pulse averaging with integrated ekg and ppg sensors - Google Patents
System and method of measuring venous oxygen saturation using intelligent pulse averaging with integrated ekg and ppg sensors Download PDFInfo
- Publication number
- CA3177643A1 CA3177643A1 CA3177643A CA3177643A CA3177643A1 CA 3177643 A1 CA3177643 A1 CA 3177643A1 CA 3177643 A CA3177643 A CA 3177643A CA 3177643 A CA3177643 A CA 3177643A CA 3177643 A1 CA3177643 A1 CA 3177643A1
- Authority
- CA
- Canada
- Prior art keywords
- signal
- ppg
- composite
- oxygen saturation
- pulse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 61
- 239000001301 oxygen Substances 0.000 title claims abstract description 61
- 238000012935 Averaging Methods 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title description 11
- 239000002131 composite material Substances 0.000 claims description 68
- 238000005070 sampling Methods 0.000 claims description 16
- 230000000747 cardiac effect Effects 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 10
- 238000004364 calculation method Methods 0.000 claims description 9
- 230000003287 optical effect Effects 0.000 claims description 6
- 230000001594 aberrant effect Effects 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 2
- 238000002565 electrocardiography Methods 0.000 abstract description 34
- 230000002503 metabolic effect Effects 0.000 abstract description 5
- 238000013186 photoplethysmography Methods 0.000 abstract description 3
- 238000011156 evaluation Methods 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 41
- 239000008280 blood Substances 0.000 description 41
- 108010054147 Hemoglobins Proteins 0.000 description 19
- 102000001554 Hemoglobins Human genes 0.000 description 19
- 238000002496 oximetry Methods 0.000 description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 14
- 210000002565 arteriole Anatomy 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 210000000038 chest Anatomy 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000006213 oxygenation reaction Methods 0.000 description 9
- 210000000264 venule Anatomy 0.000 description 9
- 230000035882 stress Effects 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000033764 rhythmic process Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 238000002106 pulse oximetry Methods 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 4
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 4
- 230000006538 anaerobic glycolysis Effects 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 238000009795 derivation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 108010061951 Methemoglobin Proteins 0.000 description 3
- 230000006536 aerobic glycolysis Effects 0.000 description 3
- 108010002255 deoxyhemoglobin Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000006609 metabolic stress Effects 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010064719 Oxyhemoglobins Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000036278 prepulse Effects 0.000 description 2
- 238000011867 re-evaluation Methods 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- -1 -oxyhemoglobin Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000022900 cardiac muscle contraction Effects 0.000 description 1
- 230000037198 cardiovascular physiology Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029039 cyanide poisoning Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910000078 germane Inorganic materials 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000037183 heart physiology Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 238000000718 qrs complex Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000009192 sprinting Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02416—Detecting, measuring or recording pulse rate or heart rate using photoplethysmograph signals, e.g. generated by infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02438—Detecting, measuring or recording pulse rate or heart rate with portable devices, e.g. worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/0245—Detecting, measuring or recording pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/25—Bioelectric electrodes therefor
- A61B5/251—Means for maintaining electrode contact with the body
- A61B5/256—Wearable electrodes, e.g. having straps or bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/25—Bioelectric electrodes therefor
- A61B5/279—Bioelectric electrodes therefor specially adapted for particular uses
- A61B5/28—Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
- A61B5/282—Holders for multiple electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/352—Detecting R peaks, e.g. for synchronising diagnostic apparatus; Estimating R-R interval
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/683—Means for maintaining contact with the body
- A61B5/6831—Straps, bands or harnesses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Signal Processing (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Optics & Photonics (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
Description
The present application claims priority to U.S. Provisional Patent Applications Serial Number 63/009,470, entitled PULSE WAVE TRANSIT TIME (PWTT) MEASUREMENT
SYSTEM USING INTEGRATED EKG AND PPG SENSORS, filed April 14, 2020, and to U.S.
Provisional Application Serial Number 63/067,147, entitled, SYSTEM FOR
IMPROVED
MEASUREMENT OF OXYGEN SATURATION, NON-INVASIVE DETECTION OF
VENOUS AND ARTERIAL PULSE WAVEFORMS, AS WELL AS DETECTION OF
CARBOXYHEMOGLOBIN, HYPERTROPHIC CARDIOMYOPATHY AND OTHER
CARDIAC CONDITIONS, filed August 18, 2020, and to U.S. Patent Application Serial number 17/135,936, entitled SYSTEMS FOR SYNCHRONIZING DIFFERENT DEVICES TO A
CARDIAC CYCLE AND FOR GENERATING PULSE WAVEFORMS FROM
SYNCHRONIZED ECG AND PPG SYSTEMS, filed December 28, 2020, the entire disclosures of which are incorporated herein by reference in their entireties for all purposes.
Technical Field of the Invention:
The present system relates to cardiac sensing systems using combined electrocardiographic (EKG) and photoplethysmographic (PPG) sensing systems.
Brief Description of the Clinical Problem:
Venous hemoglobin oxygenation in health is often greater than 80%. While this may seem surprising, this high level of oxygenation represents a metabolic reserve that the body can dip into even though a deep breath has not been taken in the last few seconds.
In states of stress that reserve will be whittled away; as such venous saturation is clinically useful as it provides a measure of the body's oxygen reserve. Currently this can only be obtained via an invasive venous blood gas measurement. Venous oxygen saturation and serum lactate are both used to measure a patient's degree of metabolic reserve and stress, as venous saturation is depressed in times of metabolic stress. Serum lactate will rise when tissues are not receiving sufficient oxygen to meet the metabolic needs, and the tissues turn to anaerobic use of glucose.
Currently, the most common measure for evaluation of metabolic stress is a serum lactate, though recent studies such as Serum Lactate Poorly Predicts Central Venous Oxygen Saturation In Critically Ill Patients: A
Retrospective Cohort Study by Bisara et. al., PMID: 21516712, DOT:
10.1186/s40560-019-0401-5, suggest venous oxygen saturation may be a better early measure of stress before onset of critical decompensation. Serum measurement of lactate, or a venous blood gas, requires aseptic blood drawing capacity and a qualified laboratory nearby capable of expeditiously running a venous sample that has been put on ice after blood draw. The capability of non-invasively measuring venous oxygenation saturation therefore has tremendous implications for assessing metabolic stress in both resource-rich and resource-limited situations.
Summary of the Invention and Cardiac Physiology Germane to the Invention:
In preferred aspects, the present system determines venous oxygen saturation in a system that comprises: (a) a device positionable against a person's skin; (b) at least one PPG sensor mounted on the device for measuring the person's PPG signal at multiple wavelengths of light; (c) a plurality of electrodes for measuring the person's EKG signal; (d) a computer logic system for receiving and analyzing the PPG signal and the EKG signal, wherein the computer logic system further comprises: (i) a system for identifying cardiac cycles in the EKG
signal; (ii) a system for segmenting the PPG signal into a series of PPG signal segments based upon features in the identified cardiac cycles, (iii) a system for sorting the PPG signal segments into a plurality of bins, each bin based upon durations of prior R-to-R cardiac cycles and current R-to-R cardiac cycles, (iv) a system for generating a composite signal for each of the plurality of bins, and (v) a system for measuring a person's venous oxygen saturation by: (a) calculating arterial oxygen saturation by comparing composite signals measured at different wavelengths of light, (b) sub-sampling composite signals at two consecutive signal maxima measured at different wavelengths of light, and (c) comparing the sub-sampled composite signals measured at different wavelengths of light to the calculated arterial oxygen saturation to determine venous oxygen saturation.
Preferably, the arterial oxygen saturation is calculated by comparing composite signals measured
In preferred aspects, the present system for measuring a person's venous oxygen saturation selects preferred bins from which the composite signals are used when calculating the person's venous oxygen saturation, and the preferred bins correspond to the bins having the largest number of PPG signal segments therein and/or the largest difference between current and prior R-to-R values. A composite signal may be generated for each bin by summing or averaging the PPG signal segments in the bin. In addition, the composite signal may be used to generate a composite Signal Prime Over Signal (SPOS) which is the derivative of the composite signal normalized by the composite signal itself. In such aspects, a system for calculating arterial oxygen saturation by comparing composite SPOS signals measured at different wavelengths of light may be included.
In preferred aspects, the system for generating a composite signal for each of the plurality of bins comprises a system for removing aberrant PPG signal segments from the calculation of the composite signal, for example, by iteratively re-calculating the composite signal, by: comparing a SPOS of each of the PPG signal segments used to calculate a composite signal against the SPOS of the calculated composite signal, removing outlier PPG signal segments, re-calculating the composite signal with the outlier PPG signal segments removed, and repeating the iteration until there are no more outlier PPG signal segments.
In various preferred physical embodiments illustrated herein, the present system is a hand-held device with the at least one PPG sensor mounted thereon and a plurality of electrode wires extending therefrom or mounted thereon. Alternatively, the present system may be positioned within a strap or band disposed around the person's chest or limb with at least one PPG sensor and the plurality of electrodes are disposed within the strap or band.
Alternatively, the present system may be disposed in a patch with the at least one PPG sensor and at least one of the plurality of electrodes positioned therein. Systems are also provided for data transmission.
The key to this analysis is understanding that the dynamics of the "tissue sandwich", through which the PPG signal is filtered, changes slightly at the end of the pulse.
This seen in FIG. 2. The curve 201 is an experimentally obtained arterial waveform, derived from a composite IR PPG
signal. As one can see, the waveform is incredibly clean, the result of intelligent similar pulse averaging over a number of minutes. The salient point is that, were the arterial pulse descent from the peak (or "roll-off') a simple exponential, or even a steady decline, the curve would not result in the "hump" seen prior to the pulse minimum just prior to the onset of the next pulse (202).
Rather than passive draining, in this time frame there is active filling of arterioles, in essence priming an "hour glass" structure consisting of the arterioles, capillaries (through which blood cells pass one-by-one), and venules. This priming effect causes a change in the composition of the blood measured by PPG oximetry. Capitalizing on this observation, that the blood composition is changing just prior to the end of the pulse, signal maxima (corresponding to arterial pulse minima) are gathered together and analyzed independently from the PPG signal obtained through the pulse. A pictorial depiction of this approach is provided in FIG. 3, showing LED sampling in FIG. 3A, standard PPG arterial hemoglobin oximetry, and FIG.
3B end-pulse/signal maxima sampling. Line 302 shows the arterial pulse sampled via standard oximetry, through which LED signal (301) sampling occurs. Line 303 is the resultant PPG
signal. Point 304 shows a signal maxima/pulse minima. FIG. 3B shows the different sampling done in end-
signal with such sampling.
Further depiction of the structure being measured at arterial end-pulse can be seen in FIG. 4.
In FIG. 4A the arteriole/capillary/venule structure is shown as an hourglass.
Through the main portion of the arterial pulse, an hourglass representing the arteriole/capillary/venule structure measured in reflective oximetry is dominated by the maximally oxygenated, pre-capillary arteriole blood (401). However, at end-pulse there is piling up of the venule, post-capillary blood, depicted in 402. FIG. 4B gives another representation of the structure, with the structure measured in reflective oximetry is shown as a shaded area (403). Also seen is a graph with a curve of the velocity of blood movement (404). This shows the blood cells slowing to their lowest velocity as they pass through the capillaries, with an asymmetry in velocity prior and post capillaries, explaining the change in arteriole to venule blood at end-pulse.
The approach is further explained in FIGS. 5A and 5B, showing changes between the sampling points (the R-to-R duration) as linear, and how the PPG signal may change. Area 501 shows the end-pulse arterial (pre-capillary) blood, and area 502 the end-pulse venous (post-capillary) blood; area 503 is the fixed elements of the structure (largely connective tissue). In FIG. 5A LED sampling through the structure at end-pulse/signal maxima (504) before and after long pulses yields PPG signals 505 and 506, separated by time 507 (R-to-R
duration). In FIG.
5B LED sampling through the structure at end-pulse/signal maxima (504) before and after short pulses yields PPG signals 508 and 509, separated by time 510 (R-to-R
duration).
The present system uses combined electrocardiography (EKG) and photoplethysmography (PPG) signals (PPG is also commonly referred to as oximetry and the two terms will be used interchangeably throughout this specification). The former senses voltage produced by heart muscle contraction, and the latter measures light absorbed by tissues. Changes in PPG signal reflect changes in blood volume and measurement at different wavelengths allows determination of oxygen saturation.
The present system allows different insight than is currently available using hand-held, portable PPG systems/devices. The combination of EKG and PPG signals in this system utilize Pulse Wave Transit Time (or PWTT), and PPG Signal Prime Over Signal (SPOS) curves. PWTT
is the period of time taken between a heartbeat as measured by the onset of the QRS complex and the time at which the blood from the aorta reaches an extremity or other body part, as determined by the negative spike generated in the SPOS curve, also described as the derivative of the LED signal divided by the signal. Use of the signal derivative to determine the change in a LED signal heralding the arrival of an arterial pulse has been described in U.S. Patent 10,213,123, assigned to MocaCare Corporation of Palo Alto, California, however use of the signal prime over signal (SPOS) allows for greater insight, as it normalizes each wavelength signal and thus allows for comparisons between different wavelength SPOS
curves.
Improved arterial oxygen saturation estimation is then generated by this system from an SPOS curve using a composite sum/average of similar pulses, with the added ability to generate oxygen saturation for selected segments of the cardiac cycle, specifically end-pulse oximetry.
Prior (n-1) EKG R-to-R duration using R-wave peaks are calculated, as are Current (n) R-to-R
duration, PWTT, and SPOS. These are all used by the present system to determine similarity of oximetry pulses, with similar pulses summed/averaged to form composite pulses, then comparing differing composite pulses to gain cardiovascular insight.
Reduced PWTT corresponds to greater pulse wave velocity, though the greater velocity does not indicate better pump function. This is because the aortic bulb acts as a "mechanical capacitor", allowing metered delivery of arterial pulse volume. However, having obtained the PWTT for any given monitoring point on the body, this metric remains relatively stable and changes only gradually barring a sudden change in cardiovascular state (e.g.
sudden change in heart rhythm such as onset of atrial fibrillation with rapid ventricular response). PWTT therefore provides a means by which to ensure accurate further data collection and analysis. This allows more reliable extraction of additional information from the combination of signals, and removal/minimization of introduced noise.
Measurement of absorption of light (per Beer-Lambert law) has the form Measurement(t) = Ke [-MO], and the signal prime over signal (SPOS) of the measurement will be: SPOS(t) = -C (cif(t)) dt The LED signals in plethysmography have the form:
(1) Signal = K * e[-tial(t)*(a*Hb)arteriall * e[-Venous(t)*E(a*Hb)venousl E(a * Hb)arterial and E (a * - - - Hb) venous describe the composition of the blood and generally change slowly. Therefore, these two terms are constants across time for the duration of our sampling. (These terms will be explained in greater detail herein).
Further, in healthy individuals, the venous flow is considered a constant.
Current oximetry measures assume this, and so will we for this initial exploration. Given this assumption, the equation reduces to:
(2) Signal = K1 * e[-Arterial(t)*E(d*Hb)arteriall Using properties of the exponential function, and of its derivative, we derive the SPOS for the PPG Signal at several wavelengths (e.g., IR and Red).
(3) SPOS(t) = (dArterial(t)) dt * (a * Hb)arterial Using the fact that the conceptual function Arterial(t) is the same for both Red and IR PPG
signals, we show that the SPOS of the signal from the IR LED (SPOS) is directly proportional to the SPOS of the signal from the Red LED (SPOSRed):
(4) SPOSRed = R * SPOS IR or SPOSRed / SPOSIR = R
Returning to the expression: E (a4Hbx* Hbx) This describes how different wavelengths of light are absorbed by the blood depending on the relative quantity of the types of hemoglobin present within.
Where:
aHbx õ = absorption coefficient for type of hemoglobin (deoxyhemoglobin, -oxyhemoglobin, carboxyhemoglobin, methemoglobin), x, for the wavelength, p.
Hbx= fractional composition of blood of various types of hemoglobin. The Sum of fractional components of different types of hemoglobin = 1.0 In the conditions of low levels of carboxyhemoglobin and methemoglobin (e.g.
excepting situations such as carbon monoxide or cyanide poisoning), and using accepted standard absorption coefficients for amHb' aRedyb, Hb = 1 - Hb02.
We end up with the equation:
(1¨ Hb02))1 The only unknown is HAD,. Solving for Hb02 gives us the fraction of the blood that is oxygenated (Arterial oxygenated hemoglobin Fraction, or Arterial Frac 02):
Any recording of EKG, or oximetry signals, or their interaction, will have physiologic variability, as well as noise. Management of EKG noise have established protocols that have been built up over 100 years. Conditioning of oximetry signals do not have as long a history.
Physiologic oximetry variability can occur from changes in venous flow (due to volitional movement, or passive movement from repositioning, or inflation/deflation of a blood pressure cuff/sphygmomanometer, etc.), respiration causing changes in intra-thoracic pressure with resultant change in blood volume return to the heart, or beat-to-beat duration variability. Noise, or non-physiologic variability, can also occur from a range of possibilities, from variation in the surface pressure and angle of application of the detector, to ambient light infection of signal collection, to DC drift of the detection circuit. Whatever the specific source of variation, without an intelligent approach to the signals, one cannot tell physiologic variability apart from non-physiologic variability (introduced noise).
Traditional means for dealing with noise introduced into oximetry signals is to filter. For example, a commonly used algorithm for detecting signal to noise ratio utilizes power within the frequencies below 20 Hz compared with power above this frequency (as described in MaximIntegrated AppNote AN6410.pdf provided by Maxim Integrated Corporation of San Jose, California). This frequency filtering highlights the underlying primary rhythm (heart rate) and smooths the appearance of the displayed waveform. However, pulses are not all the same, and treating them as if they are deletes valuable information that can be mined for deeper insight.
An alternative means by which to minimize variability is to average the oximetry over many pulses, as described in U.S. Patent 10,485,433, assigned to Intel Corporation.
This allows for minimization of introduced noise, but eliminates any information that could be gleaned from physiologic variability. This approach produces a single, homogenized, and representative pulse at the end of the process. However, pulses are not all the same, and treating them as if they are effectively obliterates some of the available information.
With the observation of FIG. 2, a re-evaluation of the assumption of a flat venous blood profile (as in equation (1)) can be done. The combination of more or less arteriole filling/emptying and more or less right ventricular filling with differing R-to-R will be seen in varying PPG signal maxima, with both venule volume and arteriole volume changing at signal maxima (FIG. 5). The ratio of arteriole and venule composition in this delta volume is not yet entirely clear. However, the approach shows that an enlarging difference between end-pulse oximetry and arterial hemoglobin oxygen saturation calculated from the rising pulse (main-pulse oximetry) reflects falling venous hemoglobin oxygen saturation.
Brief Description Of The Drawings:
FIG. 1 is a top-level flow diagram of the operation of the present system.
FIG. 2 shows a PPG signal filtered through a "tissue sandwich", showing slight changes at the end of the pulse.
FIG. 3A is an illustration of LED sampling for standard PPG arterial hemoglobin oximetry.
FIG. 3B is an illustration of end-pulse/signal maxima sampling.
FIG. 4A illustrates arteriole/capillary/venule structure is shown as an hourglass.
FIG. 4B corresponds to FIG. 4A, with the structure measured in reflective oximetry.
FIG. 5A illustrates LED sampling through the structure of FIGS. 4A and 4B at end-pulse/signal maxima before and after long pulses.
FIG. 5B illustrates LED sampling through the structure of FIGS. 4A and 4B at end-pulse/signal maxima before and after short pulses.
FIG. 6 shows the process of R-wave peak refinement used to generate tOn.
FIG. 7 shows the nomenclature and data structures used in the description of the present system.
FIG. 8 also shows the nomenclature and data structures used in the description of the present system.
FIG. 9 is an exemplary illustration of various physical components of the present system.
FIGS. 10A to 10D show various views of a hand-held embodiment of the present system, having PPG and EKG sensors mounted thereon or attached thereto.
FIG. 11 is a is a cut-away view of a portion of the device of FIGS. 10A to 10D, showing an optical waveguide adjacent to a PPG sensor.
FIG. 12A is an illustration of the system of FIGS. 10A to 11 collecting PPG
signals from a person's fingers.
FIG. 12B is an illustration of the system of FIGS. 10A to 11 collecting PPG
signals from the outside of a person's arm.
FIG. 13 is a is an illustration of EKG and PPG signals measured over time and generated SPOS
signals corresponding thereto.
FIG. 14 is a is an illustration of one-sided Gaussian fitting.
FIG. 15 illustrates the time relationship of the end-pulse/pre-pulse area of interest relative to the SPOS negative spike fitting window.
FIG. 16 illustrates a time-correlated comparison of EKG and PPG signals showing the relationships in creation of two-beat dependencies, showing current and prior "R-to-R".
FIG. 17A illustrates the number of pulses in each bin for a run of a patient with normal sinus rhythm.
FIG. 17B illustrates filling of the Current R-to-R versus Prior R-to-R matrix for purposes of determining end-pulse oximetry (the greatest difference in R-to-R duration), and the "fall-back"
or second tier bin choices using intermediate bins providing PPG signal maxima differences allowing for venous oxygen saturation estimation.
FIG. 18 is a top-level block diagram for the end-pulse/venous oxygen saturation calculation.
FIG. 19 is a is an exemplary algorithm for preparing Pulse Data Sets in accordance with the present system.
FIG. 20 illustrates the derivation of the Pulse Wave Transit Time (PWTT).
FIG. 21 shows the calculation of end-pulse/venous oxygen saturation.
FIG. 22 illustrates an exemplary embodiment of the present system disposed in a chest strap.
FIG. 23 is a is a sectional view through the patient corresponding to FIG. 22.
FIG. 24 illustrates an exemplary embodiment of the present system incorporating a bicep strap with an electrode extending therefrom.
FIG. 25 is a is a sectional view through the patient corresponding to FIG. 24.
Detailed Description of the Invention:
The central element of the system is the identification and manipulation of PPG signals on the basis of Prior R-to-R and CurrentR-to-R duration. The system them generates composite pulses from similar pulses.
In accordance with preferred aspects disclosed in U. S. Provisional patent application 62/955,196, entitled A System For Synchronizing Different Devices To A Cardiac Cycle, filed December 30, 2019 and in U.S. Patent Application Serial number 17/135,936, entitled SYSTEMS FOR SYNCHRONIZING DIFFERENT DEVICES TO A CARDIAC
CYCLE AND FOR GENERATING PULSE WAVEFORMS FROM SYNCHRONIZED ECG
AND PPG SYSTEMS, filed December 28, 2020, incorporated herein by reference in their entireties, the present system uses a specific trigger to set time = 0 for each beat (e.g. EKG R-wave peak) and then stores each pulse from this start point until completing a full cycle of sensor data, such as with LED oximetry signals from maximum to minimum and back to maximum ¨
which will be a waveform longer than a single pulse length. The next pulse waveform will have a t = 0 at the next EKG R-wave peak, thus recording of the next beat will start before the recording of the last pulse waveform has completed. In absolute terms, the time corresponding to t=0 for the nth pulse will be referred to as time tOn throughout the rest of the specification.
FIG. 6 shows the process of R-wave peak refinement used to generate tOn. The example shows how the algorithm has determined the polarity of this collection to be negative (wires reversed), and thus the R-wave to be negative. The tOn of the R-wave peak is found using polynomial fitting (602) to EKG datapoints (601) and interpolation, then used to define a Pulse Data Set.
FIG. 7 and FIG. 8 show the nomenclature and data structures used in the description (Unless otherwise specified, PWTT = PWTTIR and PPG signal = PPG signalIR). The tOn time point is then used to define a Pulse Data Set with the PPG signals of multiple wavelengths (here red, infrared, and green). Stored with the PPG signal are the values for the prior R-to-R, and current R-to-R durations, the derived signals for Signal Prime over Signal (SPOS) for each wavelength, and the Pulse Wave Transit Time (PWTT) for each wavelength. Note the first PPG
signal maxima (701) and the second PPG signal maxima (702). FIG. 8 shows the structure of the Composite Pulse Data Set, constructed from a group of Pulse Data Sets on the basis of a defined criteria (e.g. similar prior R-to-R, or current R-to-R duration). Note how the PPG waveforms are of duration longer than a single cardiac cycle, and are long enough to assure capture of both the first (801) and second PPG signal maxima (802).
FIGS. 9-11 show a preferred device implementation of the system. The device block diagram shows the elements of the device/system, with multiple wavelength LEDs (901) and a photodiode detector (902), and EKG input from electrodes (903) applied to the left and right chest (or left and right upper extremities. In preferred embodiments, signals are then fed to a processing unit (904) carrying out "on-chip" logic that then generates Composite Pulse Data Sets from raw signal. The Composite Pulse Data Sets are then communicated via either wireless or direct cable connection to an "off-device" display/computing unit (905) that provides the user with the final end-pulse oxygenation, arterial main-pulse oxygenation, and resulting venous saturation estimation with more graphical options (such as changes over time).
There is also on-device storage (906) for code as well as buffering and packetized transfer of data. In an alternate embodiment, the processing unit simply coordinates communication of raw ECG
and PPG signal data to the external computing/display device which handles all aspects of the hydration level estimation logic. In yet another embodiment, all aspects of hydration level estimation are carried out by the processing unit, including rendering of graphics and reporting of oxygen saturation.
In this case, the external computing/display device provides only the display function.
FIGS. 10A-D show various view of the PPG collection device. 1001 shows the optical waveguide (in front of LEDs and detector); 1002 shows optional incorporated EKG electrodes;
1003 shows plug-in connector sites for EKG lead wires to adhesive EKG
electrodes (on right and left chest).
FIG 11 shows detail of the PPG head, with an optical waveguide (1101) that abuts the LEDs and detector (1102) on the interior of the device. The optical waveguide allows for collection of PPG signals at sites other than the finger.
FIGS. 12A and 12B depict the device in use collecting PPG signals from the finger (FIG.
12A), and the outside of the upper arm (FIG. 12B). The PPG measurement end of the device is applied to the skin in a stable fashion so that PPG measurement can be taken over the course of 1-2 minutes or more. EKG electrodes are applied to the left and right sides of the torso (or upper extremities) and connected to the plug-ins on the smaller end of the device.
Returning to FIG. 1, PPG and EKG signals are collected. PPG waveform selection is performed to screen out aberrant beats considerably different than the majority of pulses, such as premature ventricular contraction beats, an example where the cardiac contraction does change appreciably from the beat prior.
FIG. 13 shows: EKG signal (1301); EKG R-wave peak (1302); PPG signal segments (contained within Pulse Data Sets) (1303, 1304, 1305); SPOS signals (contained within Pulse Data Sets) (1306, 1307, 1308); PWTT using SPOS (also contained within Pulse Data Sets) (1309, 1310, 1311). This demonstrates selection of one of the PPG signals (in the current implementation red, infrared, and green are used, though the approach is not limited to using these alone) with full time length for both PPG signal and SPOS longer than the R-to-R duration.
The present method and system of intelligent pulse averaging counters the effect of drift in "K" (seen in equation 1), related to absorption from fixed elements in the tissue being analyzed.
With averaging, some pulses will have an upward drift in K, some will have a downward drift, leaving the averaged pulse with more options for data point comparisons across the composite pulse width.
SPOS generates similar shaped curves for the LED signals for the different wavelengths, magnitude differing only by a multiplier that is the E (a * Hb) for the specific wavelength. The present system includes the two novel approaches of examining the SPOS signal in the region of the "negative spike" to determine:
- the linearity of the rising LED SPOS signal, or - the fit of the SPOS signal to a combination of Gaussian derivatives and/or exponential and/or polynomial equations.
Given the similar shapes for the SPOS curves, any such fitting can be applied to one wavelength to yield a fitted curve. Fitting to another wavelength only requires finding the magnitude needed to best fit that curve. For example, if f(t) best fits the infrared LED SPOS, then "A" needed to best fit A*f(t) to the SPOS for the red LED signal yields the arterial oxygen saturation just as with the equation 1. The difference with the standard formulation is that this fitting is based on many more time points (up to 50 at slower heart rates) than the two (maximum and minimum) used in the standard formulation.
FIG. 14 shows this concept using a one-sided Gaussian derivative fitting.
Curve 1401 are the datapoints of a collected Composite IR SPOS signal with a fitting window 1402 selecting out the negative SPOS "spike". Curve 1403 shows the datapoints for the window in an expanded plot, also showing the one-sided Gaussian derivative fitted curve 1404.
The interval of the fitting window selected (the SPOS "negative spike"), or subset thereof (e.g. the rising SPOS right half of the "negative spike") represents a unique period wherein a single dominant and coherent physiologic event - the contraction of the left ventricle during the time of an open aortic valve - is clearly separate from other confounding physiologic features.
This allows for extraction of parameters, which can then be applied to the entire PPG sensor pulse waveform.
The interval just preceding this fitting window for the "negative spike" of the SPOS
represents yet another unique interval, as described in the summary of the physiology above.
FIG. 15 shows the time relationship of the end-pulse/pre-pulse area of interest relative to the SPOS negative spike fitting window. Time 1501 identifies the end-pulse point;
region 1502 shows the excess SPOS PPG above expected linear or exponential "rolloff' (the shaded region of FIG. 15 corresponds to the shaded region of FIG. 2). Region 1503 identifies the window of the negative SPOS "spike" used to estimate arterial hemoglobin oxygen saturation fraction Two Beat Complex Creation for Venous Saturation Analysis:
2-beat complex selection for a longer train of pulses in atrial fibrillation (yielding random R-to-R duration) is shown in FIG. 16. Signal from a two-electrode, single lead EKG (curve 1601) is plotted in temporal alignment with an infrared (IR) LED PPG signal (curve 1602). As the infrared wavelength has relatively equivalent absorption from venous and arterial blood, this is the wavelength shown and used to select pulses for further analysis.
With accumulation of similar 2-beat complexes (based on similar n-1 R-to-R and n R-to-R
duration), composite pulse construction can be taken from one pulse minima/signal maxima all the way through to the next pulse minima/signal maxima. With this formulation, pulse minima/signal maxima at the start of the pulse and at the end of the pulse can be compared, with additional information available regarding the cardiovascular state of the individual. FIG. 16 shows the top/bottom alignment of EKG (1601) and PPG signals (1602) showing the steps in the of generation of a composite PPG wave for purposes of venous oxygen saturation derivation.
The above EKG (1601) signal shows a series of pulses labeled A through I. Each of these pulses has a different duration, though some are closer in duration than others. 2-beat dependency ties together two successive beats, with key features being the R-to-R duration of the first beat, and the PPG signal of the second beat. This is a dependency (1603) as depicted in the bracket tying together the R-to-R duration of beat "B" (1604) and the PPG
signal (1605) of beat "C". Additionally important in this analysis is the current R-to-R duration, which for this complex is the R-to-R duration of pulse "C" (1606). Notable with the bracketed complex 1603 is a paring of a long n-1 R-to-R followed by a short n R-to-R.
Pulses B and C are analyzed together, with the R-to-R duration of B and R-to-R
duration of C putting this 2-beat complex in the long n-1 R-to-R/short n R-to-R "bin".
Next, pulses C and D
are considered together, with the R-to-R duration of C and R-to-R duration of D putting this 2-beat complex in the short n-1 R-to-R/long n R-to-R "bin". Next, pulses D and E
are considered together, with the R-to-R duration of D and R-to-R duration of E putting this 2-beat complex in the long n-1 R-to-R/intermediate n R-to-R "bin". Next, pulses E and F are considered together, with the R-to-R duration of E and R-to-R duration of F putting this 2-beat complex in the intermediate n-1 R-to-R/short n R-to-R "bin". Next, pulses F and G are considered together, with the R-to-R duration of F and R-to-R duration of G putting this 2-beat complex in the short n-1 R-to-R/long n R-to-R "bin". Next, pulses G and H are considered together, with the R-to-R
duration of G and R-to-R duration of H putting this 2-beat complex in the long n-1 R-to-R/intermediate n R-to-R "bin".
As this analysis reveals, atrial fibrillation provides a wide range of permutations of n-1 R-to-R and n R-to-R duration. This allows for analysis using short-long and long-short n-1 and n R-to-R durations, the combinations that reveals the biggest changes in PPG
signal maxima.
However, with normal sinus rhythm, it is harder to select combinations that will help reveal signal maxima differences. FIG. 17A shows the number of pulses in each bin for a run of a patient with normal sinus rhythm. Note how the diagonal corresponding to the same n-1 and n R-to-R durations are most populated and the short-long and long-short bins are the least populated. FIG. 17B shows the preferential filling of the Current R-to-R
versus Prior R-to-R
matrix (1701) for purposes of determining end-pulse oximetry (the greatest difference in R-to-R
duration), and the "fall-back" or second tier bin choices using intermediate bins (1702) providing PPG signal maxima differences allowing for venous oxygen saturation estimation.
Measuring Venous Oxygen Saturation Because these 2-beat complexes define both the beginning and ending composite PPG signal, both first and second signal maxima (pulse minima) are therefore defined. And because accumulation of similar 2-beat complexes reduce the effect of DC drift, the methods described here also allow for an estimate of venous saturation. The top-level block diagram for the end-pulse/venous oxygen saturation calculation is seen in FIG. 18.
R-wave peak refinement of pulse "n" is done with curve fitting and interpolation (1801) prior to determining the prior (n-1) and current (n) R-to-R duration; then prior (n-1) and current (n) R-to-R durations for Pulse Data Set "n" are incorporated into Pulse Data Set "n"
(1802). PPG
signals are gathered, and a process of outlier rejection is carried out (including but not limited to data determined to be corrupted using accelerometer input, as well as cross-checking with multiple LED PPG sensors, 1803). Once the PPG signals of the current Pulse Data Set have been selected, the Pulse Data Set is considered together with all available prior Pulse Data Sets and their PPG signals (each of which is associated with a prior (n-1) R-to-R
duration and current (n) R-to-R duration).
Available Pulse Data Sets are then sorted into a 3 by 3 bin matrix of Prior R-to-R and Current R-to-R, each of which are considered and deemed to be short, intermediate, or long duration (1804). Dynamic boundary adjustment is used to ensure relatively equal numbers across bins, to the extent possible: normal sinus rhythm yields few Pulse Data Sets available for bins off the diagonal of short-short, intermediate-intermediate, and long-long (see FIG.
17). After all Pulse Data Sets are allocated into bins, the optimal bins are selected, e.g. those bins containing the largest number of Pulse Data Sets and those that reveal the biggest changes in signal maxima (1805). With the optimal bins established, and initial Composite Pulse Data Set is formed by adding together the corresponding PPG signals of each wavelength for each Pulse Data Set in the bin (1808).
With the Pulse Data Sets in a bin and the initial Composite Pulse Data Set in hand, a pruning loop is carried out for each bin to weed out Pulse Data Sets with noisy or otherwise aberrant PPG
signals (1806) that made it through the coarser outlier rejection. For each Pulse Data Set in the bin, and for each wavelength in the Pulse Data Set, the PWTT for the wavelength is compared against the PWTT for the wavelength for the Composite Pulse Data Set (aggregate of all the pulses). If the PWTT of two of the current three wavelengths (red, green, IR) are within 15% of the PWTT of the Composite Pulse Data Set, the Pulse Data Set is left in the composite. If not, the Pulse Data Set is rejected ("pruned") and the process is run again with the remaining Pulse Data Sets. A pruned Pulse Data Set is removed from the bin and subtracted from the Composite Pulse Data Set. If the number of Pulse Data Sets falls below a specified threshold for the number in the bin (good results have been obtained with numbers down to 4), then an additional Pulse Data Set is added prior to reporting any results. The algorithm is seen in FIG. 19. FIG. 20 shows the derivation of the Pulse Wave Transit Time (PWTT). This is done using the Signal Prime Over Signal (SPOS(t)) curve for each wavelength PPG signal(t), together with interpolation and (negative) peak refinement.
The calculation of end-pulse/venous oxygen saturation then proceeds as shown in FIG. 21.
The venous oxygen saturation calculation follows the derivation shown in Appendix B using 2-point composite signals composed of PPG signal maxima corresponding to incongruent R-to-R
duration from 2-beat complexes (1807). The results are averaged and the venous fractional oxygen saturation is reported (1809).
System Operation:
Operational alternative options are presented in the various exemplary embodiments of the present system, below. It is to be understood that the present system can be embodied in any of the systems described herein, and that the present system is not limited solely to the various exemplary embodiments described below:
FIG. 22 illustrates use of a chest strap (2201) across the chest, with incorporated electrodes (2202) contacting the left and right chest, and LED device with detector (2203).
FIG 23 illustrates cross section of a chest strap (2301) across the chest, with incorporated electrodes (2302) contacting the left and right chest, and LED device with detector (2303).
FIG. 24 illustrates use of a bicep strap (2401), with incorporated electrode (2402) and LED
device with detector (2403). A second electrode piggybacks off existing telemetry wiring (2404).
FIG 25 illustrates cross section of a bicep strap (2501), with incorporated electrode (2502) and LED device with detector (2503). A second electrode piggybacks off existing telemetry wiring (2504).
An advantage of a chest or arm strap or band is that the band/strap provides a normal force on the LED of the PPG sensor to get a good signal off the chest wall. In aspects where a chest or arm strap is used, optional "traction" may also be provided on the inside of the strap, similar to the silicone / adhesive bead that is found on the inside of standard bike shorts to keep the legs from riding up.
APPENDIX A: Cardiovascular Physiology Background In normal health, delivery of oxygen and glucose to tissues is adequate for tissues to meet their energy needs by aerobic glycolysis, a process using oxygen to breakdown glucose that releases far more energy than anaerobic glycolysis, or fermentation (metabolism of glucose without oxygen). Whereas aerobic glycolysis breaks down glucose to water and carbon dioxide, anaerobic glycolysis breaks the glucose down to lactic acid. In health lactate is low, and pH
(affected by the presence of lactic acid) is maintained around 7.4. Anaerobic metabolism with production of lactic acid allows muscles to transiently access extra energy when the tissue needs are high and there is insufficient delivery of oxygen to "burn" the available glucose (such a situation seen when sprinting at maximal effort for short distances). The lactate thus produced is then cleared from the blood stream by the liver and converted back to glucose once the physiologic stress is resolved. This allows for complete aerobic glycolysis of the previously fermented glucose.
However, when that physiologic stress is sustained rather than transient, many things begin to go awry. This can happen when infection causes the metabolism to drastically increase; or it can happen when delivery capability is suddenly reduced, as with a heart attack; it can also happen in the setting of otherwise moderate stress in the setting of baseline reduction in heart pump function. In all cases, the oxygen requirements of the tissues increase relative to what the cardiovascular system can deliver. Oxygen obtained in the lungs cannot fully replace the oxygen removed from the blood stream in the capillaries. In this situation the arterial hemoglobin oxygenation will fall ¨ though the venous saturation will fall even more due to the body eating into the oxygen reserve in the venous blood stored up prior to the stress (oxygen saturation of venous blood may exceed 80% in unstressed normal health). All of which yields a growing difference between arterial and venous oxygen.
As venous oxygenation falls further, lactate levels will eventually begin to rise, though recent studies have shown that the rising in lactate is preceded by a measurable fall in venous oxygenation, which that fall providing clinically useful information. To measure the venous blood oxygen, though, requires a venous blood gas sample. This is obtained by a blood draw that is immediately placed on ice and sent to a qualified lab. All of which is a relatively expensive and invasive procedure with a minimum turn-around time of around 10-15 minutes, if done STAT.
Circulatory shock causes inadequate oxygen delivery, resulting in mitochondrial hypoxia.
With failure of mitochondrial oxidative phosphorylation, energy metabolism becomes dependent on anaerobic glycolysis. Anaerobic glycolysis sharply increases the production of cellular lactate, and then blood levels. With severe infection, the blood lactate concentration varies in proportion to the ongoing deficit in tissue oxygenation. The ability of the patient to clear blood lactate indicates restoration of oxygen delivery with resuscitation. Studies have shown that a lactate clearance of 10% or more predicts survival from septic shock.
Studies have also shown that falling venous oxygen can provide earlier usable information than rising lactate. This unfortunately requiring ongoing invasive monitoring via a central venous line (or Swan-Ganz intracardiac catheter) and/or repeated blood draws.
APPENDIX B: Venous Hemoglobin Saturation Calculation At the pulse minima (LED signal maxima), (1) Signal max = K * lo * eHa*thickness)connectivetissuel * eHstaticarterialblood)*E(a*Hb)arterial]
(2) Signal = K * e[-ArterialPulse(t)*E(a*Hb)arteriall * e[-VenousPulse(t)*E(a*Hb)venous]
where (a * Hb)arterial and (a * Hbl 'venous are the absorption coefficients of the type of hemoglobin (deoxyhemoglobin, oxyhemoglobin, carboxyhemoglobin, methemoglobin), and E (a * Hb)arterial and E (a * Hbl 'venous are summations of absorption coefficient for each type of hemoglobin times the fraction of each type of hemoglobin making up the arterial and venous pulses (as they have different compositions, the arterial blood carrying a much higher fraction of oxygenated blood).
Collecting the LED signal maxima (A and B, separated in time by R-to-R
duration), treating them as the time varying signal, and reordering the equation:
(3) Signalmax(t) = K * lo * eHa*thickness)connectivetissuel * eHstaticarterialblood)*E(a*Hb)arteriall * eHdynamicarterialblood)*E(a*Hb)arteriall * e[-(venous(t))*E(a*Hb)venous]
With arteriole blood priming an "hour glass" structure consisting of the arterioles, capillaries, and venules toward the end of the pulse, some change in the composition of the blood toward the end of the pulse is present. This suggests that a re-evaluation of the assumption of flat venous blood profile can be done by using the following to model the change in blood composition at PPG signal maxima:
(4) delta arterial blood = gamma* delta volume (5) delta venous blood = (1-gamma)* delta volume Where gamma is somewhere between 1 and 0.5.
(6) Signalmax(t) =
Kv * eFal-gamma)*volume(t))*E(a*Hb)arteriall * e [¨(gamma*volume(0)*E(a*Hb)venous]
R B¨ t014 R) * (132+A)
2*dt E(a * Hb)venous]
Hb)venousl (dVolume(t)) 2*dt ) Once again assuming that there is only deoxyhemoglobin (Hb) and oxyhemoglobin (Hb02),
(dVolume(t)) [gamma*Z(Cr*Hb)artertal+(l-gamma)*(aHb+(axb02-aHb)*Hb02)J 2*dt ) Done at two or more different wavelengths (e.g. red, infrared, though not exclusive to these), one can solve for Hb02, given that the only unknowns are Hb02 and dVolume(t)/dt. Note that E (a * Hb)arterial at each wavelength is known from analyses done elsewhere in the system description.
(2ptSPOS(SignalmaxRed(t)))
(2ptSPOS(SignalmaxIR(M) (1¨gamma)*[¨amilb*R¨aRedHb]+gamma*[¨Z(cr*Hb)artertalIR*R+Z(IX*Hb)artertaIRedi
(1¨gamma)[R*(a¨pe iHb02¨aiRim)+(aRedim¨aRedHb02)1
Claims (16)
(a) a device positionable against a person's skin;
(b) at least one PPG sensor mounted on the device for measuring the person's PPG signal at multiple wavelengths of light;
(c) a plurality of electrodes for measuring the person's EKG signal;
(d) a computer logic system for receiving and analyzing the PPG signal and the EKG
signal, wherein the computer logic system further comprises:
(i) a system for identifying cardiac cycles in the EKG signal;
(ii) a system for segmenting the PPG signal into a series of PPG signal segments based upon features in the identified cardiac cycles, (iii) a system for sorting the PPG signal segments into a plurality of bins, each bin based upon durations of prior R-to-R cardiac cycles and current R-to-R cardiac cycles, (iv) a system for generating a composite signal for each of the plurality of bins, and (v) a system for measuring a person's venous oxygen saturation by:
(a) calculating arterial oxygen saturation by comparing composite signals measured at different wavelengths of light, (b) sub-sampling composite signals at two consecutive signal maxima measured at different wavelengths of light, and (c) comparing the sub-sampled composite signals measured at different wavelengths of light to the calculated arterial oxygen saturation to determine venous oxygen saturation.
(vi) a system for calculating arterial oxygen saturation by comparing composite SPOS
signals measured at different wavelengths of light.
comparing a SPOS of each of the PPG signal segments used to calculate a composite signal against the SPOS of the calculated composite signal, removing outlier PPG signal segments, re-calculating the composite signal with the outlier PPG signal segments removed, and repeating the iteration until there are no more outlier PPG signal segments.
sensor mounted thereon and a plurality of electrode wires extending therefrom.
a data transmission system for transmitting one or both of:
the composite signals to a remote computer system for analysis, or measured PPG and EKG signals to a remote computer system for analysis.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063009470P | 2020-04-14 | 2020-04-14 | |
US63/009,470 | 2020-04-14 | ||
US202063067147P | 2020-08-18 | 2020-08-18 | |
US63/067,147 | 2020-08-18 | ||
US17/135,936 US20210275110A1 (en) | 2019-12-30 | 2020-12-28 | Systems For Synchronizing Different Devices To A Cardiac Cycle And For Generating Pulse Waveforms From Synchronized ECG and PPG Systems |
US17/135,936 | 2020-12-28 | ||
PCT/US2021/027161 WO2021211636A1 (en) | 2020-04-14 | 2021-04-13 | System and method of measuring venous oxygen saturation using intelligent pulse averaging with integrated ekg and ppg sensors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3177643A1 true CA3177643A1 (en) | 2021-10-21 |
Family
ID=78084463
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3177643A Pending CA3177643A1 (en) | 2020-04-14 | 2021-04-13 | System and method of measuring venous oxygen saturation using intelligent pulse averaging with integrated ekg and ppg sensors |
CA3177642A Pending CA3177642A1 (en) | 2020-04-14 | 2021-04-13 | System and method of assessing intra-arterial fluid volume using intelligent pulse averaging with integrated ekg and ppg sensors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3177642A Pending CA3177642A1 (en) | 2020-04-14 | 2021-04-13 | System and method of assessing intra-arterial fluid volume using intelligent pulse averaging with integrated ekg and ppg sensors |
Country Status (2)
Country | Link |
---|---|
CA (2) | CA3177643A1 (en) |
WO (2) | WO2021211634A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130066176A1 (en) * | 2011-09-09 | 2013-03-14 | Nellcor Puritan Bennett Ireland | Venous oxygen saturation systems and methods |
US9396643B2 (en) * | 2013-10-23 | 2016-07-19 | Quanttus, Inc. | Biometric authentication |
US10478075B2 (en) * | 2013-10-25 | 2019-11-19 | Qualcomm Incorporated | System and method for obtaining bodily function measurements using a mobile device |
WO2016044685A1 (en) | 2014-09-19 | 2016-03-24 | Mocacare Corp. | Cardiovascular monitoring device |
US10398381B1 (en) * | 2015-11-19 | 2019-09-03 | Fitbit, Inc. | System and method for characterizing cardiac arrhythmia |
US10750960B2 (en) * | 2016-05-03 | 2020-08-25 | Samsung Electronics Co., Ltd. | Passive arrythmias detection based on photoplethysmogram (PPG) inter-beat intervals and morphology |
US10485433B2 (en) | 2016-12-29 | 2019-11-26 | Intel Corporation | Reliable estimation of pulse transit time in motion for cuffless blood pressure estimation |
-
2021
- 2021-04-13 WO PCT/US2021/027158 patent/WO2021211634A1/en unknown
- 2021-04-13 CA CA3177643A patent/CA3177643A1/en active Pending
- 2021-04-13 WO PCT/US2021/027161 patent/WO2021211636A1/en unknown
- 2021-04-13 CA CA3177642A patent/CA3177642A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021211636A1 (en) | 2021-10-21 |
WO2021211634A1 (en) | 2021-10-21 |
CA3177642A1 (en) | 2021-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021255871B2 (en) | System and method of measuring venous oxygen saturation using intelligent pulse averaging with integrated EKG and PPG sensors | |
US11647910B2 (en) | Body-worn system for continuous, noninvasive measurement of vital signs | |
CN109475311B (en) | Method, device and system for determining periodic physiological process frequency of subject | |
Li et al. | Characters available in photoplethysmogram for blood pressure estimation: beyond the pulse transit time | |
Lemay et al. | Application of optical heart rate monitoring | |
Wittenberg et al. | Evaluation of HRV estimation algorithms from PPG data using neural networks | |
Soerensen et al. | Challenges in using seismocardiography for blood pressure monitoring | |
CA3177643A1 (en) | System and method of measuring venous oxygen saturation using intelligent pulse averaging with integrated ekg and ppg sensors | |
Islam et al. | A non-invasive technique of early heart diseases prediction from photoplethysmography signal | |
Lazaro | Non-invasive techniques for respiratory information extraction based on pulse photoplethysmogram and electrocardiogram | |
Eerikäinen | Cardiac arrhythmia monitoring from clinical setting to daily life | |
EP4434451A1 (en) | Optical respiration rate prediction system | |
Huang | A Greedy-optimized Framework for Heart Rate Variability Monitoring during Daily Activities using Wearable Photoplethysmography | |
Li et al. | Strong robustness heart rate estimation using discrete fourier transform and personality heart rate characteristic | |
Besleaga | Photoplethysmography use for Assessment of Mechanical Alternans in Human Cardiovascular Disease | |
Sheikh et al. | Process of Detecting Chronic Diseases by using Photoplethysmogram-A Review | |
Yousefi et al. | Cardiac gating technique for arterial oxygen saturation measurement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |
|
EEER | Examination request |
Effective date: 20220928 |